Abstract
Introduction: The choice of antitumor agents used in the treatment of metastatic colorectal cancer (mCRC) is limited, which reduces the therapeutic possibilities. The improvement in survival for mCRC patient led to there is a significant number of patients progressing beyond the second or third line of treatment still suitable for further therapy when enrollment into clinical trial is not possible. In this situation, any rechallenge therapy plays an important role. We evaluated the efficacy and safety of the re-induction of oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) in the third line of chemotherapy mCRC.